AR122407A1 - Composiciones y métodos para tratar la inflamación intestinal usando un inhibidor de ccr9 y anticuerpos de bloqueo anti-il-23 - Google Patents
Composiciones y métodos para tratar la inflamación intestinal usando un inhibidor de ccr9 y anticuerpos de bloqueo anti-il-23Info
- Publication number
- AR122407A1 AR122407A1 ARP210100819A ARP210100819A AR122407A1 AR 122407 A1 AR122407 A1 AR 122407A1 AR P210100819 A ARP210100819 A AR P210100819A AR P210100819 A ARP210100819 A AR P210100819A AR 122407 A1 AR122407 A1 AR 122407A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- alkoxy
- ccr9
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 206010061218 Inflammation Diseases 0.000 title abstract 3
- 230000004054 inflammatory process Effects 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 230000000968 intestinal effect Effects 0.000 title abstract 3
- 230000000903 blocking effect Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 title 1
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 title 1
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 title 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000001475 halogen functional group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 102000009410 Chemokine receptor Human genes 0.000 abstract 2
- 108050000299 Chemokine receptor Proteins 0.000 abstract 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- -1 -OH Chemical group 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En la presente descripción se proporcionan composiciones, métodos y kits para tratar la inflamación intestinal (IBD) tal como la enfermedad de Crohn y la colitis ulcerosa en un mamífero que lo necesita. El método incluye administrar a un sujeto con IBD una terapia de combinación que contiene una cantidad terapéuticamente eficaz de un compuesto inhibidor del receptor 9 quimiocina (CCR9) y una cantidad terapéuticamente eficaz de un anticuerpo anti-IL-23. En la presente descripción también se proporciona un kit que contiene el compuesto inhibidor de CCR9 y el anticuerpo anti-IL-23. Reivindicación 1: Un método para tratar o reducir el desarrollo de la inflamación intestinal en un mamífero, dicho método comprende administrar una cantidad adecuada de un inhibidor de CCR9 con un anticuerpo de bloqueo anti-IL-23 o anti-receptor de IL-23, en donde el inhibidor del receptor de quimiocina CCR9 es un compuesto que tiene la fórmula (1) o una sal de este, donde R¹ se selecciona del grupo que consiste en alquilo C₂₋₈ sustituido o no sustituido, alcoxi C₁₋₈ sustituido o no sustituido, alquilamino C₁₋₈ sustituido o no sustituido, y heterociclilo C₃₋₁₀ sustituido o no sustituido, y; R² es H, F, Cl, o alcoxi C₁₋₈ sustituido o no sustituido; o R¹ y R² junto con los átomos de carbono a los que están unidos forman un anillo carbocíclico no aromático o un anillo heterocíclico; R³ es H, alquilo C₁₋₈ sustituido o no sustituido, alcoxi C₁₋₈ sustituido o no sustituido, o halo; R⁴ es H o F; R⁵ es H, F, Cl, o -CH₃; R⁶ es H, halo, -CN, -CO₂Rᵃ, -CONH₂, -NH₂, alquilo C₁₋₈ sustituido o no sustituido, alcoxi C₁₋₈ sustituido o no sustituido, o aminoalquilo C₁₋₈ sustituido o no sustituido; Rᵃ es H o alquilo C₁₋₈ sustituido o no sustituido; donde R⁵ y R⁶ pueden formar juntos un anillo carbocíclico; L es un enlace, -CH₂-, o -CH(CH₃)-; cada uno de A¹, A², A³, A⁴, A⁵, A⁶, A⁷, y A⁸ se selecciona independientemente del grupo que consiste en N, N-O, y -CR⁸-; donde al menos uno y no más de dos de A¹, A², A³, A⁴, A⁵, A⁶, A⁷, y A⁸ son N o N-O; R⁸ se selecciona cada uno independientemente del grupo que consiste en H, halo, -CN, -OH, oxo, alquilo C₁₋₈ sustituido o no sustituido, alcoxi C₁₋₈ sustituido o no sustituido, y -NR²⁰R²¹, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, y heterociclilo sustituido o no sustituido; y R²⁰ y R²¹ son cada uno independientemente H o alquilo C₁₋₈ sustituido o no sustituido.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063002747P | 2020-03-31 | 2020-03-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR122407A1 true AR122407A1 (es) | 2022-09-07 |
Family
ID=77921120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210100819A AR122407A1 (es) | 2020-03-31 | 2021-03-31 | Composiciones y métodos para tratar la inflamación intestinal usando un inhibidor de ccr9 y anticuerpos de bloqueo anti-il-23 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11883391B2 (es) |
| EP (1) | EP4125849A4 (es) |
| JP (1) | JP2023520048A (es) |
| KR (1) | KR20230004514A (es) |
| CN (1) | CN115484944A (es) |
| AR (1) | AR122407A1 (es) |
| AU (1) | AU2021248942A1 (es) |
| BR (1) | BR112022019958A2 (es) |
| CA (1) | CA3174350A1 (es) |
| CO (1) | CO2022015033A2 (es) |
| IL (1) | IL296956A (es) |
| MX (1) | MX2022012177A (es) |
| PE (1) | PE20230516A1 (es) |
| TW (1) | TW202203916A (es) |
| WO (1) | WO2021202731A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210154292A1 (en) * | 2019-11-21 | 2021-05-27 | Chemocentryx, Inc. | Compositions and Methods for Treating CCR9-Mediated Diseases using CCR9 Inhibitor and Anti-TNF-Alpha Blocking Antibodies |
| WO2024085697A1 (en) * | 2022-10-21 | 2024-04-25 | Chong Kun Dang Pharmaceutical Corp. | Stable antibody composition |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US5120643A (en) | 1987-07-13 | 1992-06-09 | Abbott Laboratories | Process for immunochromatography with colloidal particles |
| US6159686A (en) | 1992-09-14 | 2000-12-12 | Sri International | Up-converting reporters for biological and other assays |
| US6322901B1 (en) | 1997-11-13 | 2001-11-27 | Massachusetts Institute Of Technology | Highly luminescent color-selective nano-crystalline materials |
| US6207392B1 (en) | 1997-11-25 | 2001-03-27 | The Regents Of The University Of California | Semiconductor nanocrystal probes for biological applications and process for making and using such probes |
| US5990479A (en) | 1997-11-25 | 1999-11-23 | Regents Of The University Of California | Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes |
| US6306610B1 (en) | 1998-09-18 | 2001-10-23 | Massachusetts Institute Of Technology | Biological applications of quantum dots |
| US6251303B1 (en) | 1998-09-18 | 2001-06-26 | Massachusetts Institute Of Technology | Water-soluble fluorescent nanocrystals |
| US6326144B1 (en) | 1998-09-18 | 2001-12-04 | Massachusetts Institute Of Technology | Biological applications of quantum dots |
| US6451399B1 (en) | 2001-02-05 | 2002-09-17 | Daniel G. Boyce | Display mat |
| US7420055B2 (en) | 2002-11-18 | 2008-09-02 | Chemocentryx, Inc. | Aryl sulfonamides |
| PT1562940E (pt) * | 2002-11-18 | 2007-07-23 | Chemocentryx Inc | Sulfonamidas de arilo. |
| US7741519B2 (en) | 2007-04-23 | 2010-06-22 | Chemocentryx, Inc. | Bis-aryl sulfonamides |
| US7622583B2 (en) | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
| US7718683B2 (en) | 2006-07-14 | 2010-05-18 | Chemocentryx, Inc. | Triazolyl phenyl benzenesulfonamides |
| US7683176B2 (en) | 2006-07-14 | 2010-03-23 | Chemocentryx, Inc. | Triazolyl pyridyl benzenesulfonamides |
| PE20090717A1 (es) * | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| US7776877B2 (en) | 2007-06-22 | 2010-08-17 | Chemocentryx, Inc. | N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides |
| RS56023B1 (sr) | 2011-07-22 | 2017-09-29 | Chemocentryx Inc | Kristalni oblik natrijumove soli 4-terc-butil-n-[4-hlor-2-(1-okso-piridin-4-karbonil)-fenil]-benzensulfonamida |
| CN107266425B (zh) * | 2012-02-29 | 2020-03-03 | 坎莫森特里克斯公司 | 作为ccr9拮抗剂的吡唑-1-基苯磺酰胺 |
| KR20240033093A (ko) * | 2014-10-06 | 2024-03-12 | 케모센트릭스, 인크. | C-c 케모카인 수용체 타입 9 (ccr9)의 억제제 및 항-알파4베타7 인테그린 차단 항체의 조합 요법 |
| AR105809A1 (es) * | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos médicos |
| EP3409688A1 (en) * | 2017-05-31 | 2018-12-05 | Tillotts Pharma Ag | Topical treatment of inflammatory bowel disease using anti-tnf-alpha antibodies and fragments thereof |
| US20210154292A1 (en) | 2019-11-21 | 2021-05-27 | Chemocentryx, Inc. | Compositions and Methods for Treating CCR9-Mediated Diseases using CCR9 Inhibitor and Anti-TNF-Alpha Blocking Antibodies |
| US10792360B1 (en) | 2019-11-21 | 2020-10-06 | Chemocentryx, Inc. | Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies |
-
2021
- 2021-03-19 TW TW110109915A patent/TW202203916A/zh unknown
- 2021-03-31 MX MX2022012177A patent/MX2022012177A/es unknown
- 2021-03-31 BR BR112022019958A patent/BR112022019958A2/pt unknown
- 2021-03-31 US US17/219,172 patent/US11883391B2/en active Active
- 2021-03-31 WO PCT/US2021/025171 patent/WO2021202731A1/en active Application Filing
- 2021-03-31 AU AU2021248942A patent/AU2021248942A1/en active Pending
- 2021-03-31 AR ARP210100819A patent/AR122407A1/es unknown
- 2021-03-31 IL IL296956A patent/IL296956A/en unknown
- 2021-03-31 CN CN202180032060.XA patent/CN115484944A/zh active Pending
- 2021-03-31 EP EP21780180.2A patent/EP4125849A4/en active Pending
- 2021-03-31 PE PE2022002163A patent/PE20230516A1/es unknown
- 2021-03-31 JP JP2022559875A patent/JP2023520048A/ja active Pending
- 2021-03-31 CA CA3174350A patent/CA3174350A1/en active Pending
- 2021-03-31 KR KR1020227036340A patent/KR20230004514A/ko unknown
-
2022
- 2022-10-21 CO CONC2022/0015033A patent/CO2022015033A2/es unknown
-
2023
- 2023-12-06 US US18/531,086 patent/US20240100041A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL296956A (en) | 2022-12-01 |
| JP2023520048A (ja) | 2023-05-15 |
| BR112022019958A2 (pt) | 2022-11-22 |
| PE20230516A1 (es) | 2023-03-24 |
| EP4125849A1 (en) | 2023-02-08 |
| MX2022012177A (es) | 2022-12-02 |
| US20240100041A1 (en) | 2024-03-28 |
| CN115484944A (zh) | 2022-12-16 |
| US20210308119A1 (en) | 2021-10-07 |
| AU2021248942A1 (en) | 2022-11-17 |
| CO2022015033A2 (es) | 2022-10-31 |
| US11883391B2 (en) | 2024-01-30 |
| TW202203916A (zh) | 2022-02-01 |
| WO2021202731A1 (en) | 2021-10-07 |
| EP4125849A4 (en) | 2024-04-17 |
| CA3174350A1 (en) | 2021-10-07 |
| KR20230004514A (ko) | 2023-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR122407A1 (es) | Composiciones y métodos para tratar la inflamación intestinal usando un inhibidor de ccr9 y anticuerpos de bloqueo anti-il-23 | |
| AR118374A1 (es) | Inhibidores de la proteína tirosina fosfatasa y métodos para usarlos | |
| AR111689A1 (es) | Tienopiridinas y benzotiofenos útiles como inhibidores de irak4 | |
| AR121044A1 (es) | Inhibidores de egfr | |
| AR109788A1 (es) | Compuestos de benzo[b]tiofeno como agonistas de sting | |
| AR112834A1 (es) | Derivados de rapamicina | |
| AR114793A1 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos | |
| AR115296A1 (es) | Heterocíclicos inhibidores de mat2a y métodos de uso para el tratamiento del cáncer | |
| AR098721A1 (es) | Inhibidores de biarilo de tirosina quinasa de bruton | |
| AR107032A1 (es) | Inhibidores bicíclicos de pad4 | |
| AR111808A1 (es) | Derivados de pirimidina como moduladores del receptor de pge2 | |
| AR112468A1 (es) | Carboxamidas como inhibidores de proteasa específicos de ubiquitina | |
| AR116464A1 (es) | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 | |
| AR119594A1 (es) | Derivados de tienopirimidina como inhibidores acc y usos de los mismos | |
| AR094497A1 (es) | Compuestos tetracíclicos sustituidos con tiofeno y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| AR117539A1 (es) | INHIBIDORES DE TGF-bR1 (ALK5) ÚTILES PARA TRATAR TRASTORNOS DE PROLIFERACIÓN CELULAR | |
| AR118521A1 (es) | Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de trastornos inflamatorios | |
| AR121744A1 (es) | MODULADORES DE a 1-ANTITRIPSINA | |
| AR119376A1 (es) | Compuestos heterocíclicos | |
| AR112794A1 (es) | Compuestos heteroaromáticos sustituidos con cicloolefinas y su uso en el tratamiento de enfermedades inducidas por mutaciones idh | |
| AR124189A1 (es) | Compuestos y procedimientos de uso de los mismos | |
| AR120170A1 (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
| AR123933A1 (es) | Derivados de isoxazol como moduladores del receptor de serotonina 5-ht₂a útiles para el tratamiento de trastornos relacionados con el mismo | |
| AR123932A1 (es) | Derivados de pirimidina como moduladores del receptor de la serotonina 5-ht₂a útiles para el tratamiento de trastornos relacionados con el mismo | |
| AR110252A1 (es) | Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam |